Spectral Medical (TSE:EDT – Get Free Report) released its quarterly earnings results on Friday. The company reported C($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of C$0.28 million during the quarter.
Spectral Medical Stock Down 2.0%
EDT stock opened at C$0.97 on Friday. The company has a debt-to-equity ratio of 26.03, a current ratio of 0.61 and a quick ratio of 0.45. The stock has a market capitalization of C$284.75 million, a price-to-earnings ratio of -8.08 and a beta of 0.86. The business’s fifty day moving average price is C$1.13 and its two-hundred day moving average price is C$1.30. Spectral Medical has a fifty-two week low of C$0.86 and a fifty-two week high of C$1.54.
About Spectral Medical
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ (‘PMX’). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date.
Featured Stories
- Five stocks we like better than Spectral Medical
- The Ugly Truth Behind SoundHound’s Q3 Results
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.
